On August 8, 2019 InnoCure Therapeutics (CEO Hye-dong Yoo) reported the company is accelerating the development of new drugs using next-generation target protein degradation mechanisms (Press release, InnoCure Therapeutics, AUG 8, 2019, View Source;nid=233623 [SID1234651740]). According to the company, they are conducting research to develop treatments for rare diseases including anticancer drugs and degenerative brain diseases by utilizing next-generation new drug development technologies such as ‘PROTAC’ and ‘AUTOTAC’, artificial intelligence (AI) to shorten drug development time and increase drug efficacy, big data analysis, and molecular modeling to induce specific protein degradation mechanisms.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Based on this, InnoCure Therapeutics was recognized for its technological prowess when it was selected for the R&D project of the Ministry of SMEs and Startups’ TIPS program in February 2019, in which Magna Investment participated as the operator.
The company said that it has secured several new substances effective in the field of rare diseases at the research institute that moved to Pangyo, Gyeonggi-do in June, and is currently pursuing IND application for clinical trials in 2021. It is also pursuing joint research with pharmaceutical and bio companies specializing in degenerative brain diseases and rare diseases in the United States.
"InnoCure is actively utilizing PROTAC and AUTOTAC, next-generation technologies that can serve as ‘game changers’ in the new drug development field," said Bae Jun-hak, Vice President of Magna Investment. "The management team, which has experience in global bio companies and a global human network, possesses the know-how in global market entry strategies."
Meanwhile, PROTAC targeted protein degradation technology is known as a drug development technology that can increase efficacy and reduce side effects with small doses. Avinas, founded in 2014 by Professor Craig Crews of Yale University, a pioneer in PROTAC technology, became the first PROTAC technology company to enter clinical trials with a drug using PROTAC technology when its prostate cancer treatment under development received clinical approval from the FDA in March 2019.
InnoCure Therapeutics CEO Yoo Hye-dong is currently conducting clinical research on a drug for degenerative brain diseases that was jointly researched with a U.S. East Coast biotech company specializing in degenerative brain diseases while working at NCE Sciences, a San Francisco-based startup in the U.S. While working at Celgene, she participated in the development of new drugs, including the development of an alternative to the blockbuster nano-oncology drug ‘Abraxane.’
In January 2018, he founded Innocure Therapeutics.